Wire · opportunities
Atacicept Slows IgAN Decline to Physiologic Rate, With Sayna Norouzi, MD
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 September 2026 · Fusion42 review
The phase 3 ORIGIN 3 trial showed that atacicept (Trutakna) slowed kidney function decline to a physiologic rate and reduced the risk of kidney disease progression by 76% compared to placebo in adults with primary IgA nephropathy (IgAN). Vera Therapeutics plans to submit for full FDA approval in Q4 2026 based on these positive long-term kidney outcome data.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a clear regulatory pathway opening in IgA nephropathy treatment as full FDA approval for atacicept looms in Q4 2026. Biotech founders in kidney disease should prepare to engage with payers and providers on long-term kidney function benefits beyond proteinuria reduction.
◆ Coverage
1 source · 29 Sep 2026
◆ Related on Wire
◆ Topics